Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface

Xuewu Zhang, Kerry A. Pickin, Ron Bose, Natalia Jura, Philip A. Cole, John Kuriyan

Research output: Contribution to journalArticle

236 Citations (Scopus)

Abstract

Members of the epidermal growth factor receptor family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy. Critical for activation is the formation of an asymmetric dimer by the intracellular kinase domains, in which the carboxy-terminal lobe (C lobe) of one kinase domain induces an active conformation in the other. The cytoplasmic protein MIG6 (mitogen-induced gene 6; also known as ERRFI1) interacts with and inhibits the kinase domains of EGFR and ERBB2 (refs 3-5). Crystal structures of complexes between the EGFR kinase domain and a fragment of MIG6 show that a ∼25-residue epitope (segment 1) from MIG6 binds to the distal surface of the C lobe of the kinase domain. Biochemical and cell-based analyses confirm that this interaction contributes to EGFR inhibition by blocking the formation of the activating dimer interface. A longer MIG6 peptide that is extended C terminal to segment 1 has increased potency as an inhibitor of the activated EGFR kinase domain, while retaining a critical dependence on segment 1. We show that signalling by EGFR molecules that contain constitutively active kinase domains still requires formation of the asymmetric dimer, underscoring the importance of dimer interface blockage in MIG6-mediated inhibition.

Original languageEnglish (US)
Pages (from-to)741-744
Number of pages4
JournalNature
Volume450
Issue number7170
DOIs
StatePublished - Nov 29 2007

Fingerprint

Epidermal Growth Factor Receptor
Phosphotransferases
Mitogens
Epitopes
Peptides
Genes
Neoplasms
Proteins

ASJC Scopus subject areas

  • General

Cite this

Zhang, X., Pickin, K. A., Bose, R., Jura, N., Cole, P. A., & Kuriyan, J. (2007). Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature, 450(7170), 741-744. https://doi.org/10.1038/nature05998

Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. / Zhang, Xuewu; Pickin, Kerry A.; Bose, Ron; Jura, Natalia; Cole, Philip A.; Kuriyan, John.

In: Nature, Vol. 450, No. 7170, 29.11.2007, p. 741-744.

Research output: Contribution to journalArticle

Zhang, X, Pickin, KA, Bose, R, Jura, N, Cole, PA & Kuriyan, J 2007, 'Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface', Nature, vol. 450, no. 7170, pp. 741-744. https://doi.org/10.1038/nature05998
Zhang, Xuewu ; Pickin, Kerry A. ; Bose, Ron ; Jura, Natalia ; Cole, Philip A. ; Kuriyan, John. / Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. In: Nature. 2007 ; Vol. 450, No. 7170. pp. 741-744.
@article{ddcd1bb8c5d94c9b84b0ab38e59ecd31,
title = "Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface",
abstract = "Members of the epidermal growth factor receptor family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy. Critical for activation is the formation of an asymmetric dimer by the intracellular kinase domains, in which the carboxy-terminal lobe (C lobe) of one kinase domain induces an active conformation in the other. The cytoplasmic protein MIG6 (mitogen-induced gene 6; also known as ERRFI1) interacts with and inhibits the kinase domains of EGFR and ERBB2 (refs 3-5). Crystal structures of complexes between the EGFR kinase domain and a fragment of MIG6 show that a ∼25-residue epitope (segment 1) from MIG6 binds to the distal surface of the C lobe of the kinase domain. Biochemical and cell-based analyses confirm that this interaction contributes to EGFR inhibition by blocking the formation of the activating dimer interface. A longer MIG6 peptide that is extended C terminal to segment 1 has increased potency as an inhibitor of the activated EGFR kinase domain, while retaining a critical dependence on segment 1. We show that signalling by EGFR molecules that contain constitutively active kinase domains still requires formation of the asymmetric dimer, underscoring the importance of dimer interface blockage in MIG6-mediated inhibition.",
author = "Xuewu Zhang and Pickin, {Kerry A.} and Ron Bose and Natalia Jura and Cole, {Philip A.} and John Kuriyan",
year = "2007",
month = "11",
day = "29",
doi = "10.1038/nature05998",
language = "English (US)",
volume = "450",
pages = "741--744",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "7170",

}

TY - JOUR

T1 - Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface

AU - Zhang, Xuewu

AU - Pickin, Kerry A.

AU - Bose, Ron

AU - Jura, Natalia

AU - Cole, Philip A.

AU - Kuriyan, John

PY - 2007/11/29

Y1 - 2007/11/29

N2 - Members of the epidermal growth factor receptor family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy. Critical for activation is the formation of an asymmetric dimer by the intracellular kinase domains, in which the carboxy-terminal lobe (C lobe) of one kinase domain induces an active conformation in the other. The cytoplasmic protein MIG6 (mitogen-induced gene 6; also known as ERRFI1) interacts with and inhibits the kinase domains of EGFR and ERBB2 (refs 3-5). Crystal structures of complexes between the EGFR kinase domain and a fragment of MIG6 show that a ∼25-residue epitope (segment 1) from MIG6 binds to the distal surface of the C lobe of the kinase domain. Biochemical and cell-based analyses confirm that this interaction contributes to EGFR inhibition by blocking the formation of the activating dimer interface. A longer MIG6 peptide that is extended C terminal to segment 1 has increased potency as an inhibitor of the activated EGFR kinase domain, while retaining a critical dependence on segment 1. We show that signalling by EGFR molecules that contain constitutively active kinase domains still requires formation of the asymmetric dimer, underscoring the importance of dimer interface blockage in MIG6-mediated inhibition.

AB - Members of the epidermal growth factor receptor family (EGFR/ERBB1, ERBB2/HER2, ERBB3/HER3 and ERBB4/HER4) are key targets for inhibition in cancer therapy. Critical for activation is the formation of an asymmetric dimer by the intracellular kinase domains, in which the carboxy-terminal lobe (C lobe) of one kinase domain induces an active conformation in the other. The cytoplasmic protein MIG6 (mitogen-induced gene 6; also known as ERRFI1) interacts with and inhibits the kinase domains of EGFR and ERBB2 (refs 3-5). Crystal structures of complexes between the EGFR kinase domain and a fragment of MIG6 show that a ∼25-residue epitope (segment 1) from MIG6 binds to the distal surface of the C lobe of the kinase domain. Biochemical and cell-based analyses confirm that this interaction contributes to EGFR inhibition by blocking the formation of the activating dimer interface. A longer MIG6 peptide that is extended C terminal to segment 1 has increased potency as an inhibitor of the activated EGFR kinase domain, while retaining a critical dependence on segment 1. We show that signalling by EGFR molecules that contain constitutively active kinase domains still requires formation of the asymmetric dimer, underscoring the importance of dimer interface blockage in MIG6-mediated inhibition.

UR - http://www.scopus.com/inward/record.url?scp=36749011864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749011864&partnerID=8YFLogxK

U2 - 10.1038/nature05998

DO - 10.1038/nature05998

M3 - Article

VL - 450

SP - 741

EP - 744

JO - Nature

JF - Nature

SN - 0028-0836

IS - 7170

ER -